HomeNewsBusinessDouble-digit growth with profitability is the focus in FY22: Mindtree CEO

Double-digit growth with profitability is the focus in FY22: Mindtree CEO

The strategy is in execution mode right now and we are seeing very good traction in terms of the deals that we are winning — not only new logos, but also in existing accounts, where we are able to mine those accounts by cross-selling and upselling, says Debashis Chatterjee, CEO & Managing Director, Mindtree.

April 19, 2021 / 10:15 IST
Story continues below Advertisement

L&T-owned software firm Mindtree closed the fourth quarter with 5.2 percent sequential growth even as its travel and hospitality vertical continued to see pressure in the aftermath of the pandemic. Under the 4x4x4 strategy, which was implemented last year, the company is confident of achieving double-digit growth in FY22.

In this interaction with Moneycontrol, Debashis Chatterjee, CEO & Managing Director, Mindtree, spoke about its growth and hiring outlook. Edited excerpts: 

Story continues below Advertisement

Travel, transportation and the hospitality sector accounted for 16 percent of your revenues before the pandemic. That has shrunk to about 10 percent in Q4 FY21. How is the sector looking and what is your outlook?

We have been talking about how it will be several quarters before TTH can come back to (pre-)pandemic levels. But having said that, if you look at our exposure to travel, we have quite a few clients in travel and hospitality, where we have been working with them for over a decade. We never lost any client during the pandemic —revenues were down, but we never lost any client.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show